Resmed Reports Q3 2026 Financial Results
Key points
- Net revenue of $1.41 billion, up 6.7% year-over-year
- Net income of $418.4 million, up 20.1% year-over-year
- Diluted earnings per share of $2.92
- Cash and cash equivalents at $1.01 billion
Full summary
Resmed Inc. reported its Q3 2026 financial results, showing a net revenue of $1.41 billion, an increase of 6.7% compared to the same period last year. The company reported a net income of $418.4 million, up 20.1% year-over-year, and diluted earnings per share of $2.92. Cash and cash equivalents stood at $1.01 billion. The company's sleep and breathing health products contributed $1.26 billion in net revenue, while residential care software brought in $155 million. Operating expenses were $417.6 million, and the company paid $95 million in dividends.
Guidance
Resmed expects full-year revenue to be between $5.5 billion and $5.6 billion
Outlook
Resmed anticipates continued growth in both sleep and breathing health products and residential care software segments.
Summary generated by a large language model. Please interpret with care.